Synonym:LY2784544;LY2784544;LY-2784544;Gandotinib.

IUPAC/ChemicalName:3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine

InChiKey:SQSZANZGUXWJEA-UHFFFAOYSA-N

InChiCode:InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h4-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)

SMILESCode:CC1=NNC(NC2=NN3C(C(CN4CCOCC4)=C2)=NC(C)=C3CC5=CC=C(Cl)C=C5F)=C1

TechnicalData

AdditionalInformation

  LY2784544haspotentialfordevelopmentasatargetedagentagainstJAK2V617FandmayhavepropertiesthatallowsuppressionofJAK2V617F-inducedMPNpathogenesiswhileminimizingeffectsonhematopoieticProgenitorcells.LY2784544iscurrentlyunderclinicaltrialsforparticipantswithmyeloproliferativeneoplasms.
 
 

References

1:RosenthalA,MesaRA.Januskinaseinhibitorsforthetreatmentofmyeloproliferativeneoplasms.ExpertOpinPharmacother.2014Jun;15(9):1265-76.doi:10.1517/14656566.2014.913024.Epub2014Apr25.PubMedPMID:24766055.

2:FurqanM,MukhiN,LeeB,LiuD.DysregulationofJAK-STATpathwayinhematologicalmalignanciesandJAKinhibitorsforclinicalapplication.BiomarkRes.2013Jan16;1(1):5.doi:10.1186/2050-7771-1-5.PubMedPMID:24252238;PubMedCentralPMCID:PMC3776247.

3:MaL,ClaytonJR,WalgrenRA,ZhaoB,EvansRJ,SmithMC,Heinz-TahenyKM,KreklauEL,BloemL,PitouC,ShenW,StrelowJM,HalsteadC,RempalaME,ParthasarathyS,GilligJR,HeinzLJ,PeiH,WangY,StancatoLF,DowlessMS,IversenPW,BurkholderTP.DiscoveryandcharacterizationofLY2784544,asmall-moleculetyrosinekinaseinhibitorofJAK2V617F.BloodCancerJ.2013Apr12;3:e109.doi:10.1038/bcj.2013.6.PubMedPMID:23584399;PubMedCentralPMCID:PMC3641321.

4:TamCS,VerstovsekS.InvestigationalJanuskinaseinhibitors.ExpertOpinInvestigDrugs.2013Jun;22(6):687-99.doi:10.1517/13543784.2013.774373.Epub2013Feb23.Review.PubMedPMID:23432430.

5:TrelińskiJ,RobakT.JAKinhibitors:pharmacologyandclinicalactivityinchronicmyeloprolipherativeneoplasms.CurrMedChem.2013;20(9):1147-61.PubMedPMID:23317159.

6:SantosFP,VerstovsekS.JAK2inhibitorsformyelofibrosis:whyaretheyeffectiveinpatientswithandwithoutJAK2V617Fmutation?AnticancerAgentsMedChem.2012Nov;12(9):1098-109.Review.PubMedPMID:22583424.

7:PassamontiF,MaffioliM,CaramazzaD.Newgenerationsmall-moleculeinhibitorsinmyeloproliferativeneoplasms.CurrOpinHematol.2012Mar;19(2):117-23.doi:10.1097/MOH.0b013e32834ff575.Review.PubMedPMID:22227528.